ENVALITH
ジェイフロンティア株式会社 logo

J Frontier Co.,Ltd.

2934・Growth Market・Foods

Official website
ジェイフロンティア株式会社 logo
J Frontier Co.,Ltd.2934

Business

J Frontier Corporation is a healthcare-focused company established in 2008. Centered on "SOKUYAKU," a medical platform providing online medical consultations, medication guidance, and prescription drug delivery in a one-stop service, the company operates three businesses: D2C mail-order sales of health foods and pharmaceuticals (including the "Koh Suiso 328 Sen" and "Seikansen®" series), and marketing support and BPO for healthcare operators. Consolidated net sales for FY2025 (ended May 2025) were ¥21,504 million (up 21.4% year on year). Under its corporate philosophy of "Making people and society healthy and beautiful," the company has built a suite of services covering the entire "healthcare cycle," from pre-symptomatic care and prevention through to disease management.

Business Model

①Medical Care Sales: Revenue from SOKUYAKU platform usage fees (collected from both patients and medical institutions) and pharmaceutical D2C subscription purchases. ②Healthcare Sales: Secures stable revenue through a subscription membership model for health foods and cosmetics. ③Healthcare Marketing: Receives orders from corporate clients for B2B support services such as celebrity casting, TV shopping, direct mail distribution, and logistics BPO. Manufacturing is outsourced via OEM, and logistics is outsourced to external warehouses, forming an asset-light model. The company thoroughly manages advertising investment through CPO control for efficient operations.

Company Strengths

SOKUYAKU, which launched in February 2021, achieved a user count increase of over 200% year-on-year in FY2025 (ended May 2025). Even after the system usage fee revision implemented in June 2024, customer churn was minimal, achieving a simultaneous increase in usage volume and per-user unit price. Segment EBITDA turned positive, rising from ¥-142 million in the prior period to ¥551 million.

The non-face-to-face and EC operation know-how developed through D2C mail-order sales has been applied to the SOKUYAKU business, forming a vertically integrated business structure in which the Marketing Support Business provides side support for sales promotion across the entire group. In the fourth quarter of FY2025 (ended May 2025), QAU (Quarterly Active Unique Users) reached 280,000, and ARR (Annual Recurring Revenue) reached ¥9.6 billion.

Revenue in the Healthcare Marketing Business for FY2025 (ended May 2025) was ¥9,687 million (up 53.0% year-on-year). Celebrity casting, TV shopping, DM marketing, and logistics BPO all contributed in combination. The consolidation of shake-hands Co., Ltd. as a subsidiary (with goodwill of ¥792 million recorded) also contributed to the expansion of segment scale.

ENVALITH's Perspective

The net loss attributable to owners of the parent of ¥321 million for FY2026 (ending March 2026) [note: source figure refers to fiscal year ending May 2026] was mainly attributable to a one-time goodwill amortization of ¥435 million (special loss) in the Healthcare Sales Business. Operating profit was ¥312 million (up 6.3% year on year) and ordinary profit was ¥415 million (up 79.3% year on year), indicating continued improvement on a core business basis. While non-operating income, including a gain on sale of investment securities of ¥179 million, boosted ordinary profit, a heavy tax burden of ¥175 million significantly weighed down the bottom line. The one-time goodwill amortization is a non-recurring loss, and trends in operating profit and EBITDA will be a key benchmark for assessing the earnings recovery in FY2027 (ending March 2027).

The company forecasts net sales of ¥26,500 million (up 19.2% year on year), operating profit of ¥1,050 million (up 236.2% year on year), and net income of ¥550 million for FY2027 (ending March 2027). The policy is to aim for "profit growth exceeding sales growth," centered on the Medical Care Sales Business, with the SOKUYAKU business as the growth driver. However, in FY2026 (ending March 2026), both the Medical Care Sales Business and the Healthcare Sales Business saw net sales decline by 7.9% and 11.5% year on year, respectively, making trends in new customer acquisition costs and existing customer retention rates in the D2C business key factors for achieving the forecast. External factors such as soaring prices and uncertainty over US trade policy could also affect consumer behavior.

At the end of FY2026 (ending March 2026), the equity ratio stood at 12.8% (down from 15.3% in the previous fiscal year), net assets were ¥1,534 million, and retained earnings reflected an accumulated deficit of ¥2,604 million. Short-term borrowings increased by ¥815 million year on year to ¥2,107 million, and while financing cash flow secured a positive ¥758 million due to the increase in borrowings, reliance on interest-bearing debt is rising. There is no note regarding going concern assumptions at this time, but financial flexibility would be limited should the substantial profit growth forecast for FY2027 (ending March 2027) fail to be achieved. It should also be noted that the amortization burden of goodwill of ¥853 million (provisional figure) arising from the acquisition of shake-hands will continue for the next seven years.

Growth Strategy

Expanding the SOKUYAKU healthcare economic zone and maximizing synergies between the D2C and B2B businesses

While sustaining the effect of the system usage fee price revision, the company is expanding new B2B revenue sources such as broader corporate adoption of SOKUYAKU Benefit and its incorporation into school-trip plans. In FY2027 (ending May 2027), the company aims for profit growth exceeding sales growth, centered on the Medical Care Sales business with the SOKUYAKU business as its growth driver.

In the pharmaceuticals, health foods, and cosmetics D2C business, the company made advertising investments in Q4 aimed at generating revenue in the following fiscal year. It will continue advertising investment for new subscription customer acquisition and CRM improvement measures, seeking to raise retention rates and average spend per customer among subscription members. The Healthcare Sales business has struggled, with FY2026 revenue down 11.5% year on year, making recovery an urgent priority.

Leveraging the expertise of shake-hands Co., Ltd. (EC mall support and content marketing), acquired in September 2025, the company aims to promote cross-selling to B2B business clients and to enhance marketing measures for the SOKUYAKU and D2C businesses. Acquisition cost was ¥1,231 million, with goodwill of ¥853 million (provisional) arising, to be amortized evenly over 7 years.

The company has set Quarterly Active Users (QAU) and Annual Recurring Revenue (ARR) as key management indicators, aiming to expand the scale of its economic zone by growing the user base of its BtoC services. Management has indicated that in FY2027 (ending May 2027), the results of upfront investments are expected to be reflected in performance.

Last updated: July 17, 2026